Company intelligence / Profile preview

Tiantai Yinkang Biopharmaceutical

Tiantai, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Tiantai Yinkang Biopharmaceutical is a China-based clinical-stage biotechnology company focused on the development of innovative small molecule therapeutics for metabolic diseases. The company's lead candidate, Janagliflozin (Yinkang-001), is a highly selective SGLT2 inhibitor currently in late-stage clinical development for the treatment of type 2 diabetes. Tiantai Yinkang aims to provide high-quality, affordable treatment options for chronic metabolic conditions within the Chinese market. The company operates research and development facilities in Zhejiang province and maintains a focus on internal drug discovery and clinical validation.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Tiantai Yinkang Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiantai Yinkang Biopharmaceutical.

Explore the full profile